key: cord-0884690-v0499l9f
authors: Kow, Chia Siang; Hasan, Syed Shahzad
title: Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One
date: 2021-05-05
journal: Chest
DOI: 10.1016/j.chest.2020.11.073
sha: 958e069f95216d108de7b819f417b146c8bb150e
doc_id: 884690
cord_uid: v0499l9f

nan

Henkel et al 2 speculated that the observation of enlarged pulmonary arteries might be related to an increase of parenchymal and predominantly intravascular pressure, due to severe COVID-19 pulmonary microangiopathy that affected the alveolar capillary network. The high incidence of microthrombosis was also thought to be suggestive of a possible underestimation of the vascular alterations associated with COVID-19 with the use of imaging, especially on unenhanced scans. 2 Henkel et al 2 concluded that both severe acute lung injury and vascular complications contribute to fatal outcomes. These considerations largely resonate with the excellent remarks by Rotzinger and Qanadli. 1 Perhaps the most surprising finding from the study was the reduced risk of death with the administration of both corticosteroids and tocilizumab. 1 Such findings cannot be treated as if the beneficial effects are arising solely from the corticosteroids because the observed risk reduction was even greater than the risk reduction with corticosteroid alone (HR, 0.44; 95% CI, 0.35-0.55); it implied that there must be some forms of synergism that exist between corticosteroids and tocilizumab in patients with COVID-19. Similarly, this synergism had also been suggested in a randomized controlled trial 3 of tocilizumab in patients with COVID-19, in which the primary analysis observed no difference on day 28 mortality rate with tocilizumab compared with usual care (HR, 0.92; 95% CI, 0.33-2.53), but the subgroup analysis revealed a reduced risk of death in patients who receive tocilizumab plus dexamethasone compared with those who receive usual care plus dexamethasone (HR, 0.13; 95% CI, 0.021-0.78).

Narain et al 1 failed to highlight this finding that could have very significant clinical implications. The mechanism that underlies the synergism between corticosteroids and tocilizumab is unclear, but we postulate that reduced bioactivity to corticosteroids for some reason and in at least certain patients with COVID-19 could lead to failure of corticosteroids to retard the effects IL-6, because IL-6 has been shown to be inhibited by corticosteroids. This reduced bioactivity may or may not be related to polymorphisms in the IL-6 gene (IL-6 174GG genotype) that has been associated with resistance to corticosteroids. 4 In addition, administration of corticosteroids had also been shown to contribute to an enhanced IL-6-induced proinflammatory acutephase response. 5 We believe that the routine combination of corticosteroids with tocilizumab is worthy of more evaluation of its clinical outcomes in patients with COVID-19.

To the Editor:

We thank Drs Kow and Hasan for their critique of our article. 1 Our study highlighted the benefit of corticosteroids in reducing hospital deaths of patients with coronavirus disease 2019 (COVID-19) cytokine storm compared with standard of care (which did not include any steroids). Further, our study suggests a decreased mortality rate associated with corticosteroids plus tocilizumab when compared with corticosteroids alone.

We agree with the authors that there may be a synergistic effect with the combination of corticosteroids and tocilizumab. Our study was not designed to evaluate this effect due to the lack of standardization of drug dose, frequency, and timing of drug administration that were not controlled for in the observational analysis. Despite our attempts to control rigorously for confounders, there may have been inherent patient or treatment differences that may have contributed to outcomes.

Although we did not have the data on the interval between initial COVID-19 symptoms and the onset of hyperinflammatory state, our analysis shows that, after the onset of "cytokine storm," steroids were given earlier than chestjournal.org

Chest CT imaging signature of coronavirus disease 2019 infection: in pursuit of the scientific evidence

Lethal COVID-19: radiological-pathological correlation of the lungs

Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Comparative survival analysis of immunomodulatory therapy for coronavirus disease 2019 cytokine storm

Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial

Does cytokine gene polymorphism affect steroid responses in idiopathic nephrotic syndrome?

Glucocorticoids increase interleukin-6-dependent gene induction by interfering with the expression of the suppressor of cytokine signaling 3 feedback inhibitor